Definitive Contract 75N91025C00021
Award Date
9/15/25
Potential Completion Date
9/14/26
Potential Value
$355K
Federal Agency
National Cancer Institute
Awardee
Tippingpoint Biosciences, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Los Altos Hills, CA 94022, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
52
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
This is a $300,000 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Coordination Pharmaceuticals Inc., a small business. The contract is for the detection, diagnosis, treatment, prevention, and research of pediatric cancers and/or rare cancers. It was awarded under a Small Business Innovation Research (SBIR) Concept Award Program, which is a "Phase 0" pilot program intended to encourage small businesses to develop innovative and...
This is a Small Business Innovation Research (SBIR) Concept Award issued by the National Cancer Institute, a civilian agency, for the development of therapeutic or preventative technologies to treat or prevent pediatric cancers and/or rare cancers. The $354,957.00 Firm Fixed Price contract was awarded to Metaclipse Therapeutics Corp, a self-certified small disadvantaged business, on September 5, 2025, with a completion date of September 4, 2026. The contract is set aside for total small business...
This is a Small Business Innovation Research (SBIR) Concept Award from the National Cancer Institute (NCI), a civilian agency, to Pathcision Medicine, Inc., a minority-owned, woman-owned small business. The $354,941 firm-fixed-price contract is for the development of a novel delivery approach to transform the treatment and prevention of metastatic pancreatic cancer. The award is associated with a pre-solicitation opportunity that will focus on the development of innovative technologies for the...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services. The $355,000 Firm Fixed Price contract was awarded to Insilicom LLC, a minority-owned and woman-owned small business, to develop a proof-of-concept technology for drug repurposing targeting rare cancers using a large-scale, high-quality biomedical knowledge graph. The original contract opportunity was a...
The National Cancer Institute (NCI) awarded a $353,102 Firm Fixed Price contract to Angstrom Research Inc., a self-certified small disadvantaged business, for a Phase I SBIR (Small Business Innovation Research) Concept Award. The contract, identified as 75N91024C00012, is part of the NCI's SBIR program and is focused on the development of innovative therapeutic technologies, devices, or diagnostics for the treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers. This is a...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Nomocan Pharmaceuticals LLC, a for-profit limited liability company, for $354,959. The contract is for the development of a therapeutic technology, device, or diagnostic technology to treat, detect, or diagnose pediatric cancers and rare cancers with survival rates below 50%. The contract has a firm fixed-price pricing type...
This is a Small Business Innovation Research (SBIR) Concept Award from the National Cancer Institute (NCI), a civilian agency, to Qana Therapeutics Inc. The $354,672 Firm Fixed Price contract is for the development of therapeutic technologies targeting ferroptosis inducers for the treatment of adrenocortical carcinoma, a rare cancer type. The contract is part of the NCI's SBIR Innovative Concept Award Program, which seeks innovative and potentially transformative technologies for the...
This $400,000 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Amplifidx Inc., a woman-owned small business. The contract supports the development of cancer prevention and diagnosis technologies for low-resource settings over a two-year period. This award aligns with NCI's mission to support innovative medical device research and development by small businesses. As a SBIR...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...